TURNOVER OF ARSEUS INCREASED BY 26.6% TO € 101.3 MILLION, FAGRON GROWTH OF 30.7% AND REALISES STRONG ORGANIC GROWTH OF 13.3%

Waregem (Belgium) / Rotterdam (The Netherlands)[1], 8 April 2014 -In the first quarter of 2014, the consolidated turnover of Arseus increased by 26.6% (at constant exchange rates) to € 101.3 million. Organic growth was 12.0% (at constant exchange rates).

The evolution of turnover[2] per division is as follows:

x 1,000 euros Q1 2014 Q1 2013 Total
growth Tot. growth
constant* Org. growth Org. growth
constant** Fagron 88,274 71,573 23.3% 30.7% 6.9% 13.3% Corilus 10,577 10,276 2.9% 2.9% 2.9% 2.9% HL Technology 2,494 2,360 5.7% 5.3% 5.7% 5.3% Total 101,345 84,209 20.4% 26.6% 6.4% 12.0%

* Total growth at constant exchange rates ** Organic growth at constant exchange rates

Ger van Jeveren, Arseus CEO: “Arseus had an excellent start of 2014 with turnover growth of 26.6% and organic turnover growth of no less than 12.0%. The continuous strategic focus on innovation, own brands and concepts with substantial added value has had a positive impact on the development of Arseus’ turnover during the first quarter of 2014. Fagron’s strong organic growth is the result of the successful introduction of new concepts, vehicles and formulations for pharmaceutical compounding and the increasing growth of Fagron Compounding Services. In 2014, Fagron will further strengthen its position as global market leader through robust organic growth and an active buy-and-build strategy. Corilus saw an increase in recurring licensing revenues due to growth in the number of users of its software suites for medical professionals. This clearly confirmed that the focus on improving the quality of the turnover and on high-margin ICT solutions has been successful. We look to the future with confidence and confirm the expectations for 2014 that we announced earlier.”

[1] This press release was sent out by Arseus NV and Arseus BV.
[2] Unaudited management figures on the basis of continuing operations.

For further information:
Marieke Palstra
Director Investor Relations
+ 31 88 33 11 213
marieke.palstra@arseus.com

Please open the link below for the press release: